Literature DB >> 11444846

Macrophage colony-stimulating factor suppresses osteoblast formation.

M Gyda1, S Corisdeo, M Zaidi, B R Troen.   

Abstract

We provide the first evidence that the bone marrow-derived cytokine, macrophage colony-stimulating factor (M-CSF), inhibits the formation of bone-forming osteoblasts. We examined both osteoclast and osteoblast formation in primary rat bone marrow cultures. As expected, M-CSF together with osteoprotegerin ligand (OPGL) markedly accelerated osteoclastogenesis. In contrast, treatment with M-CSF alone yielded no osteoclasts at any time. The most striking and novel observation was that M-CSF with or without OPGL dramatically suppressed osteoblast formation. In separate experiments, estradiol markedly suppressed osteoclast formation in the M-CSF/OPGL-treated cultures independently of osteoblasts. Consistent with this was the expression of estrogen receptor-alpha (ERalpha) and ERbeta mRNA in osteoclast precursors. We therefore conclude that in addition to the well-known action of M-CSF to modulate osteoclastogenesis, this cytokine may also regulate osteoblast formation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444846     DOI: 10.1006/bbrc.2001.5128

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts.

Authors:  Y Wittrant; Y Gorin; S Mohan; B Wagner; S L Abboud-Werner
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

2.  Suppressive effects of Anoectochilus formosanus extract on osteoclast formation in vitro and bone resorption in vivo.

Authors:  Kikuko Masuda; Mayumi Ikeuchi; Tomoyuki Koyama; Kohji Yamaguchi; Je-Tae Woo; Tomio Nishimura; Kazunaga Yazawa
Journal:  J Bone Miner Metab       Date:  2008-02-27       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.